Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Nu-3

Other · developed by Lakewood-Amedex

Phase 2 Most advanced trial

LABT Developer

3 Registered trials

What is Nu-3?

Nu-3 (Bisphosphocin) is a topical gel applied once or twice daily to infected diabetic foot ulcers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Therapy area: Endocrine
Developer: Lakewood-Amedex Inc (LABT)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: 8BK3483OW5

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06020235	Phase 2	Diabetic Foot Infection	Not yet recruiting	LABT
NCT05276401	Phase 2	Chronic Diabetic Foot Ulcers	Terminated	LABT
NCT02737722	Phase 1/2	Diabetic Foot Infections	Completed	LABT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diabetic Foot InfectionChronic Diabetic Foot Ulcers

Sources

ClinicalTrials.gov NCT06020235

Updated Oct 3, 2026. Something wrong or missing? Report it on the LABT page.

Follow LABT, the company behind Nu-3

See LABT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LABT catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z